Puma Biotechnology, Inc. (NASDAQ: PBYI) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
7.80
+0.11+1.43%
TA
Loading chart...
Snapshot
| Index | - | P/E | 16.25 | EPS (ttm) | 0.48 | Insider Own | 29.57% | Shs Outstand | 50.90M | Perf Week | -2.13% |
| Market Cap | 397.02M | Forward P/E | 39.00 | EPS next Y | 0.20 | Insider Trans | -0.94% | Shs Float | 38.90M | Perf Month | -5.11% |
| Enterprise Value | 311.02M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 10.05% | Perf Quarter | 3.59% |
| Income | 24.00M | P/S | 1.76 | EPS this Y | -39.58% | Inst Trans | - | Short Ratio | 13.22 | Perf Half Y | 14.37% |
| Sales | 226.00M | P/B | 3.10 | EPS next Y | -31.03% | ROA | 12.65% | Short Interest | 3.91M | Perf YTD | 31.09% |
| Book/sh | 2.51 | P/C | 3.89 | EPS next 5Y | - | ROE | 20.37% | 52W High | 8.75 -10.86% | Perf Year | 154.07% |
| Cash/sh | 2.00 | P/FCF | 7.53 | EPS past 3/5Y | 210.89% - | ROIC | 17.12% | 52W Low | 3.04 156.58% | Perf 3Y | 117.27% |
| Dividend Est. | - | EV/EBITDA | 6.91 | Sales past 3/5Y | 0.00% 0.27% | Gross Margin | 74.46% | Volatility | 4.06% 4.97% | Perf 5Y | -0.13% |
| Dividend TTM | - | EV/Sales | 1.38 | EPS Y/Y TTM | -22.58% | Oper. Margin | 12.98% | ATR (14) | 0.37 | Perf 10Y | -81.22% |
| Dividend Ex-Date | - | Quick Ratio | 2.24 | Sales Y/Y TTM | -1.74% | Profit Margin | 10.73% | RSI (14) | 46.66 | Recom | 2.79 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.38 | EPS Q/Q | -140.00% | SMA20 | -3.44% | Beta | 1.21 | Target Price | - |
| Payout | 0.00% | Debt/Eq | 0.22 | Sales Q/Q | -2.17% | SMA50 | 1.24% | Rel Volume | 0.86 | Prev Close | 7.69 |
| Employees | 179 | LT Debt/Eq | 0.04 | Earnings | Aug 06 | SMA200 | 17.85% | Avg Volume | 311.74K | Price | 7.80 |
| IPO Date | Apr 24, 2012 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 76.47% 6.67% | Net Debt/EBITDA | -0.45 | Volume | 269,411 | Change | 1.43% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy | |
| Oct-08-19 | Downgrade | Goldman Sachs | Neutral → Sell | |
| May-10-19 | Downgrade | Citi | Buy → Neutral | |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral | |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral | |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral | |
| Nov-19-18 | Upgrade | Goldman Sachs | Sell → Neutral | |
| Nov-02-18 | Downgrade | Barclays | Equal Weight → Underweight | |
| Apr-12-18 | Downgrade | Barclays | Overweight → Equal Weight | |
| Jan-24-18 | Downgrade | Cowen & Co. | Outperform → Market Perform |
Latest News
Jul-30-26
Jul-23-26
Jul-23-2604:10PM
Jul-07-26
Company
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 226 | 228 | 230 | 236 | 228 | 253 | 225 | 272 | 251 | |
| Cost of Goods Sold Incl. D&A | 57 | 58 | 64 | 63 | 55 | 64 | 39 | 37 | 35 | |
| Gross Profit | 168 | 170 | 166 | 173 | 173 | 189 | 186 | 235 | 216 | |
| Selling, General and Administrative Excl. Other | 71 | 71 | 80 | 89 | 90 | 116 | 118 | 142 | 146 | |
| Research and Development | 68 | 62 | 55 | 50 | 52 | 72 | 98 | 133 | 165 | |
| Other Operating Expense | 0 | 0 | 0 | 1 | 7 | 0 | 0 | 36 | 0 | |
| Operating Income | 30 | 37 | 31 | 33 | 24 | 1 | -30 | -76 | -95 | |
| Interest Expense | 5 | 7 | 12 | 13 | 12 | 13 | 14 | 15 | 11 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 4 | 5 | 6 | 3 | -12 | -17 | -15 | 15 | -8 | |
| Net Income Before Taxes | 29 | 36 | 24 | 23 | 0 | -29 | -60 | -76 | -114 | |
| Income Taxes | 4 | 5 | -6 | 1 | 0 | 0 | 0 | 0 | -8 | |
| Consolidated Net Income | 24 | 31 | 30 | 22 | 0 | -29 | -60 | -76 | -114 | |
| Net Income From Continuing Operations | 24 | 31 | 30 | 22 | 0 | -29 | -60 | -76 | -114 | |
| Net Income | 24 | 31 | 30 | 22 | 0 | -29 | -60 | -76 | -114 | |
| EPS (Recurring) | 0.50 | 0.62 | 0.62 | 0.46 | 0.02 | -0.72 | -1.52 | -2.13 | -2.99 | |
| EPS (Basic, Before Extraordinaries) | 0.50 | 0.62 | 0.62 | 0.46 | 0.02 | -0.72 | -1.52 | -2.13 | -2.99 | |
| EPS (Diluted) | 0.48 | 0.61 | 0.62 | 0.45 | 0.02 | -0.72 | -1.52 | -2.13 | -2.99 | |
| EBITDA | 45 | 53 | 48 | 48 | 22 | -5 | -36 | -52 | -95 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 16.25 | 9.75 | 4.92 | 9.62 | 208.37 | — | — | — | — | |
| Price To Sales Ratio | 1.76 | 1.30 | 0.65 | 0.86 | 0.83 | 0.49 | 1.82 | 1.25 | 3.08 | |
| Gross Margin | 74.34 | 74.56 | 72.17 | 73.31 | 75.88 | 74.70 | 82.67 | 86.40 | 86.06 | |
| Operating Margin | 13.27 | 16.23 | 13.48 | 13.98 | 10.53 | 0.40 | -13.33 | -27.94 | -37.85 | |
| Net Margin | 10.62 | 13.60 | 13.04 | 9.32 | 0.00 | -11.46 | -26.67 | -27.94 | -45.42 | |
| Shares Outstanding | 51 | 50 | 49 | 47 | 45 | 41 | 40 | 39 | 38 | |
| Market Capitalization | 398 | 298 | 149 | 204 | 190 | 125 | 410 | 341 | 773 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| AUERBACH ALAN H | President and CEO | Jul 06 '26 | Sale | 8.26 | 44,058 | 364,051 | 7,261,671 | Jul 08 |
| HUNT DOUGLAS M | See Remarks | Jul 06 '26 | Sale | 8.26 | 8,460 | 69,905 | 196,841 | Jul 08 |
| NOUGUES MAXIMO F | Chief Financial Officer | Jul 06 '26 | Sale | 8.26 | 9,386 | 77,557 | 230,637 | Jul 08 |
| MOYES JAY M | Director | Jun 12 '26 | Sale | 7.22 | 22,000 | 158,796 | 58,322 | Jun 15 |
| WILSON TROY EDWARD | Director | Jun 12 '26 | Sale | 7.20 | 10,800 | 77,748 | 59,750 | Jun 15 |
| Stuglik Brian M | Director | Jun 12 '26 | Sale | 7.20 | 8,100 | 58,311 | 113,858 | Jun 15 |
| Senderowicz Adrian | Director | Jun 12 '26 | Sale | 7.20 | 27,000 | 194,311 | 27,000 | Jun 15 |
| Dorval Allison | Director | Jun 12 '26 | Sale | 7.20 | 11,610 | 83,579 | 90,780 | Jun 15 |
| AUERBACH ALAN H | President and CEO | Jan 07 '26 | Sale | 5.88 | 18,012 | 105,893 | 7,145,951 | Jan 08 |
| NOUGUES MAXIMO F | Chief Financial Officer | Jan 07 '26 | Sale | 5.88 | 6,405 | 37,655 | 193,284 | Jan 08 |
| HUNT DOUGLAS M | See Remarks | Jan 07 '26 | Sale | 5.88 | 5,014 | 29,477 | 155,907 | Jan 08 |
| AUERBACH ALAN H | President and CEO | Jan 06 '26 | Sale | 5.84 | 16,938 | 98,986 | 7,163,963 | Jan 08 |
| HUNT DOUGLAS M | See Remarks | Jan 06 '26 | Sale | 5.84 | 3,973 | 23,218 | 160,921 | Jan 08 |
| NOUGUES MAXIMO F | Chief Financial Officer | Jan 06 '26 | Sale | 5.84 | 4,540 | 26,532 | 199,689 | Jan 08 |
| MILLER MICHAEL PATRICK | Director | Nov 11 '25 | Sale | 4.86 | 20,000 | 97,228 | 54,000 | Nov 13 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.